Trending NewsTrending NewsNASDAQ:ACAD ACADIA Pharmaceuticals (ACAD) Stock Price, News & Analysis $24.40 +0.60 (+2.52%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$24.52 +0.12 (+0.49%) As of 08/7/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About ACADIA Pharmaceuticals Stock (NASDAQ:ACAD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ACADIA Pharmaceuticals alerts:Sign Up Key Stats Today's Range$23.28▼$24.5350-Day Range$20.88▼$24.4052-Week Range$13.40▼$25.23Volume2.15 million shsAverage Volume1.66 million shsMarket Capitalization$4.08 billionP/E Ratio18.35Dividend YieldN/APrice Target$28.00Consensus RatingModerate Buy Company Overview ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California. Read More ACADIA Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks80th Percentile Overall ScoreACAD MarketRank™: ACADIA Pharmaceuticals scored higher than 80% of companies evaluated by MarketBeat, and ranked 212th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingACADIA Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.61, and is based on 10 buy ratings, 6 hold ratings, and 1 sell rating.Amount of Analyst CoverageACADIA Pharmaceuticals has been the subject of 15 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about ACADIA Pharmaceuticals' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth8.57% Earnings GrowthEarnings for ACADIA Pharmaceuticals are expected to grow by 8.57% in the coming year, from $0.70 to $0.76 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ACADIA Pharmaceuticals is 18.35, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 27.80.Price to Earnings Ratio vs. SectorThe P/E ratio of ACADIA Pharmaceuticals is 18.35, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 29.88.Price to Earnings Growth RatioACADIA Pharmaceuticals has a PEG Ratio of 6.64. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioACADIA Pharmaceuticals has a P/B Ratio of 5.55. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted6.86% of the outstanding shares of ACADIA Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverACADIA Pharmaceuticals has a short interest ratio ("days to cover") of 5.3.Change versus previous monthShort interest in ACADIA Pharmaceuticals has recently decreased by 10.52%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldACADIA Pharmaceuticals does not currently pay a dividend.Dividend GrowthACADIA Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted6.86% of the outstanding shares of ACADIA Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverACADIA Pharmaceuticals has a short interest ratio ("days to cover") of 5.3.Change versus previous monthShort interest in ACADIA Pharmaceuticals has recently decreased by 10.52%, indicating that investor sentiment is improving significantly. News and Social Media2.5 / 5News Sentiment0.52 News SentimentACADIA Pharmaceuticals has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 20 news articles for ACADIA Pharmaceuticals this week, compared to 9 articles on an average week.Search InterestOnly 1 people have searched for ACAD on MarketBeat in the last 30 days. This is a decrease of -90% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added ACADIA Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, ACADIA Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $454,634.00 in company stock.Percentage Held by Insiders26.50% of the stock of ACADIA Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.71% of the stock of ACADIA Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ACADIA Pharmaceuticals' insider trading history. Receive ACAD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ACADIA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ACAD Stock News HeadlinesACADIA Pharmaceuticals Inc. (ACAD) Q2 2025 Earnings Call TranscriptAugust 7 at 5:03 AM | seekingalpha.comAcadia Pharma Q2 2025 Earnings PreviewAugust 7 at 4:08 AM | seekingalpha.comAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Trump’s Great Gain” has officially begun. Altucher believes select cryptos could turn $900 into $108,000 over the next 12 months — and he’s laying out the full gameplan in a new presentation. | Paradigm Press (Ad)Acadia raises 2025 NUPLAZID guidance to $665M–$690M as DAYBUE accelerates community uptakeAugust 7 at 4:08 AM | seekingalpha.comACADIA Pharmaceuticals Inc. 2025 Q2 - Results - Earnings Call PresentationAugust 7 at 3:58 AM | seekingalpha.comAcadia (ACAD) Q2 Revenue Rises 9%August 6 at 11:48 PM | fool.comAcadia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operating OverviewAugust 6 at 4:05 PM | businesswire.comAcadia Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth ConferenceAugust 5 at 4:05 PM | businesswire.comSee More Headlines ACAD Stock Analysis - Frequently Asked Questions How have ACAD shares performed this year? ACADIA Pharmaceuticals' stock was trading at $18.35 at the beginning of the year. Since then, ACAD shares have increased by 33.0% and is now trading at $24.40. How were ACADIA Pharmaceuticals' earnings last quarter? ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) issued its quarterly earnings results on Wednesday, August, 6th. The biopharmaceutical company reported $0.16 earnings per share for the quarter, topping analysts' consensus estimates of $0.14 by $0.02. The company's revenue for the quarter was up 9.4% compared to the same quarter last year. Read the conference call transcript. Who are ACADIA Pharmaceuticals' major shareholders? Top institutional investors of ACADIA Pharmaceuticals include Assenagon Asset Management S.A. (1.02%), Bank of New York Mellon Corp (0.48%), Connor Clark & Lunn Investment Management Ltd. (0.38%) and Emerald Advisers LLC (0.35%). Insiders that own company stock include Bros Advisors Lp Baker, Stephen Davis, Mark C Schneyer, Brendan Teehan, Srdjan R Stankovic, Austin D Kim, James Kihara, Elizabeth A Garofalo and Laura Brege. View institutional ownership trends. How do I buy shares of ACADIA Pharmaceuticals? Shares of ACAD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ACADIA Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that ACADIA Pharmaceuticals investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AU Optronics (AUOTY). Company Calendar Last Earnings8/06/2025Today8/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ACAD CIK1070494 Webwww.acadia-pharm.com Phone(858) 558-2871Fax858-558-2872Employees510Year FoundedN/APrice Target and Rating Average Price Target for ACADIA Pharmaceuticals$28.38 High Price Target$40.00 Low Price Target$20.00 Potential Upside/Downside+18.1%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage17 Analysts Profitability EPS (Trailing Twelve Months)$1.37 Trailing P/E Ratio17.43 Forward P/E Ratio34.32 P/E Growth6.6Net Income$226.45 million Net Margins22.97% Pretax Margin26.58% Return on Equity17.46% Return on Assets10.75% Debt Debt-to-Equity RatioN/A Current Ratio2.88 Quick Ratio2.80 Sales & Book Value Annual Sales$957.80 million Price / Sales4.20 Cash Flow$0.72 per share Price / Cash Flow33.54 Book Value$4.40 per share Price / Book5.46Miscellaneous Outstanding Shares167,360,000Free Float123,011,000Market Cap$4.02 billion OptionableOptionable Beta0.70 Social Links 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:ACAD) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredThe Day Silicon DiesThe Day China Left America's Supercomputers in the Dust In 200 seconds, China's quantum computer accomplish...The Oxford Club | SponsoredThis accelerated income plan is solving American's #1 retirement fearThe #1 fear in retirement today? Running out of money. That’s why income expert Tim Plaehn created a simple...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ACADIA Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ACADIA Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.